Focus Issue: Angiotensin-Neprilysin Inhibition: Novel InsightsClinical ResearchEfficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The PIONEER-HF trial was funded by Novartis Pharmaceutical Corp. For the work under consideration, Dr. Braunwald reports grant support to his institution from Novartis for the conduct of the PIONEER-HF Trial, for his serving on the Executive Committee of the PARADISE trial, the Steering Committee of the PARAGLIDE trial, and for his participation in an Advisory Board meeting; outside the submitted work; reports grants to his institution from AstraZeneca, Daiichi Sankyo, and Merck; and has received personal fees for consultancies with Amgen, Cardurion, MyoKardia, NovoNordisk, and Verve Dr. DeVore has received research funding from AstraZeneca, Amgen, the American Heart Association, Bayer, Luitpold Pharmaceuticals, Medtronic, the National Heart, Lung, and Blood Institute (NHLBI), PCORI, and Novartis; and has served as a consultant for AstraZeneca, LivaNova, Mardil Medical, Novartis, and Procyrion. Dr. Pinney has received consulting fees from Abbott, CareDx, and Medtronic. Dr. Duffy is an employee of Novartis Pharmaceuticals Corp. Dr. Gurmu has received grant support from Novartis. Dr. Velazquez has received grants from Novartis, Amgen, Phillips, and NHLBI/National Institutes of Health. Dr. Morrow has received grants from Abbott Laboratories, Amgen, AstraZeneca, Eisai, GlaxoSmithKline, Medicines Company, Merck, Novartis, Pfizer, Roche Diagnostics, and Takeda; and has received personal fees from Abbott Laboratories, Aralez, AstraZeneca, Bayer Pharma, GlaxoSmithKline, InCarda, Merck, Peloton, and Roche Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.